University of Maryland School of Medicine - Center for Vaccine Development - Baltimore
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Memoli, Matthew J
NCT05027932: Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

Completed
1
45
US
IN Placebo, IM Placebo, BPL-1357
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
03/24
03/24
NCT05436444: Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

Recruiting
1
200
US
A/Mallard/Ohio-99/MM4/1989 H10N7
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Infection
10/25
10/25
NCT01386424: Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Recruiting
N/A
5000
US
National Institute of Allergy and Infectious Diseases (NIAID)
Zika, Influenza
 
 
NCT05266222: Respiratory Virus Sampling and Repository

Recruiting
N/A
20000
US
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, COVID-19
12/31
12/31
Ortiz, Justin
IN-NE-rH5, NCT05397119: A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

Completed
1
40
US
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
BlueWillow Biologics, University of Maryland, Baltimore, National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Pandemic
10/23
10/23
NCT05870839: Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

Completed
1
121
US
VXCO-100
Vaccine Company, Inc.
SARS-CoV, SARS-CoV-2
04/24
04/24
Campbell
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
NCT05740982: A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Active, not recruiting
2
450
US
JYNNEOS
National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
08/24
06/25

Download Options